title: Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
abstract: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The most common cause of mortality in patients with NAFLD or NASH is cardiovascular disease (CVD). Currently, the treatment of NAFLD focuses on gradual weight loss and life style modifications. However, multifactorial treatment of NAFLD or NASH risk factors may be needed to reduce the likelihood of these patients developing CVD. This review discusses the mechanisms that link hyperlipidemia and NAFLD. In addition, the review focuses on the safety and efficacy of statins in patients with NAFLD or NASH, and their effect on the extent of hepatic steatosis and fibrosis based on human studies.
authors: Department of Internal Medicine, Holy Family Hospital, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed Israel, POB 8, Nazareth, 16100, Israel. w.nseir@yahoo.com
authors: William
authors: W
authors: Nseir
authors: Mahmud
authors: M
authors: Mahamid
mesh_terms: D018450:Disease Progression; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D065626:Non-alcoholic Fatty Liver Disease; D011379:Prognosis
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors